A new anti-aging biotech wants to add 10 years to your life. But who's funding it?

Kyle LaHucik

Senior Reporter

Another relatively mysterious anti-aging biotech has emerged and the details are once again slim. Retro Biosciences said it has reeled in an initial pool of $180 million, but the investors remain anonymous.

Those funds are expected to bankroll first proofs of concept and “operation of the company through the decade,” the Redwood City, CA biotech said late Tuesday night in a Twitter post and update on its website. The posts collectively alerted the world to Retro’s lofty mission: “add 10 years to healthy human lifespan.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

BECOME A PREMIUM SUBSCRIBER

TRENDING NOW

A new anti-aging biotech wants to add 10 years to your life. But who's funding it?

Kyle LaHucik

Senior Reporter

Unlock this article instantly by becoming a free subscriber.

Autoimmune patients in CAR-T study see striking improvements across lupus and other diseases

As cash runs tight, bluebird plunges after pricing sickle cell gene therapy well above competitor and failing to win ...

Roche partner touts early allogeneic CAR-T data at #ASH23, but durability remains key question

FDA approves two gene therapies for sickle cell disease, including first that uses CRISPR

How one lab's decadeslong search for the 'holy grail' of sickle cell led to the first CRISPR therapy

Solid Tumors: The Next Frontier of Cancer Immuno-therapy

A new an­ti-ag­ing biotech wants to add 10 years to your life. But who's fund­ing it?

Kyle LaHucik

Senior Reporter

Unlock this article instantly by becoming a free subscriber.

Au­toim­mune pa­tients in CAR-T study see strik­ing im­prove­ments across lu­pus and oth­er dis­eases

As cash runs tight, blue­bird plunges af­ter pric­ing sick­le cell gene ther­a­py well above com­peti­tor and fail­ing to win ...

Roche part­ner touts ear­ly al­lo­gene­ic CAR-T da­ta at #ASH23, but dura­bil­i­ty re­mains key ques­tion

FDA ap­proves two gene ther­a­pies for sick­le cell dis­ease, in­clud­ing first that us­es CRISPR

How one lab's decades­long search for the 'holy grail' of sick­le cell led to the first CRISPR ther­a­py

Sol­id Tu­mors: The Next Fron­tier of Can­cer Im­muno-ther­a­py

A new anti-aging biotech wants to add 10 years to your life. But who's funding it?

Autoimmune patients in CAR-T study see striking improvements across lupus and other diseases

As cash runs tight, bluebird plunges after pricing sickle cell gene therapy well above competitor and failing to win ...

Roche partner touts early allogeneic CAR-T data at #ASH23, but durability remains key question

FDA approves two gene therapies for sickle cell disease, including first that uses CRISPR

How one lab's decadeslong search for the 'holy grail' of sickle cell led to the first CRISPR therapy

Solid Tumors: The Next Frontier of Cancer Immuno-therapy